Morningstar Investment Management LLC cut its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 21.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 257,882 shares of the biopharmaceutical company’s stock after selling 68,676 shares during the quarter. Morningstar Investment Management LLC’s holdings in Pfizer were worth $6,421,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the stock. Triad Wealth Partners LLC grew its position in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares in the last quarter. ETF Store Inc. grew its position in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares in the last quarter. Mattern Wealth Management LLC grew its position in shares of Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares in the last quarter. Pines Wealth Management LLC grew its position in shares of Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares in the last quarter. Finally, Pathway Financial Advisers LLC grew its position in shares of Pfizer by 0.9% in the fourth quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 403 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.
Key Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer’s Phase 3 Lyme vaccine trial is nearing completion, which could be an important step toward a new potential growth driver if the data are supportive. Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know
- Positive Sentiment: Pfizer is also advancing a broader pneumococcal vaccine strategy, including positive Phase 2 infant data and a new Phase 3 pediatric program, which supports the company’s long-term vaccine franchise. Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)
- Positive Sentiment: Pfizer’s HYMPAVZI expansion in Europe and the new Rigel licensing arrangement for VEPPANU add to the company’s revenue opportunities beyond its legacy products. Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
- Neutral Sentiment: Pfizer is testing new tablet formulations for tafamidis and migraine treatments in early-stage bioequivalence studies, which are routine development updates but do not yet imply a major commercial impact. Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study
- Neutral Sentiment: Pfizer also disclosed an observational biosimilar study in Japan, another incremental pipeline item that appears more informational than immediately market-moving. Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch
- Negative Sentiment: Pfizer ended an early Phase 1 KRAS cancer trial, which may be viewed as a setback in one of the company’s closely watched oncology programs. Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors
- Negative Sentiment: Some analyst coverage continues to flag patent risk and competitive pressure, which may limit enthusiasm despite the recent pipeline progress. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
Pfizer Price Performance
Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the business earned $0.92 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is presently 131.30%.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. CICC Research assumed coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Bank of America reduced their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. Barclays assumed coverage on Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Finally, HSBC boosted their target price on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.61.
Check Out Our Latest Research Report on Pfizer
Pfizer Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Read More
- Five stocks we like better than Pfizer
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
